Matthew J. Frank, MD, PhD, on Large B-Cell Lymphoma: New Data on CD22 CAR T-Cell Therapy

July 31, 2023 By The ASCO Post Staff

Matthew J. Frank, MD, PhD, of Stanford University School of Medicine, discusses new findings showing that CD22 chimeric antigen receptor (CAR) T-cell therapy is an effective and safe salvage therapy for patients with CAR19-refractory large B-cell lymphoma. A multicenter phase II clinical trial is planned for 2023 (Abstract S230).

Related Content